Supplementary table 1. Antiphospholipid antibodies of aPL patients according to the FXI:C levels.

	FXI:C <70% (N= 13)	**FXI:C >150% (N= 18)**	***p***
LA N (%)	10 (76.9)	13 (72.2)	1.00
LA only N(%)	6 (46.2)	6 (33.3)	0.470
aCL			
IgM N (%)	2 (15.4)	3 (16.7)	0.924
IgG N (%)	3 (23.1)	3 (16.7)	0.656
IgM and/or IgG N(%)	4 (30.8)	7 (38.9)	0.641
IgM and IgG N(%)	1 (7.7)	0 (0)	0.232
aCL only N(%)	0 (0)	1 (5.6)	0.388
a*β*2GP1			
IgM N(%)	3 (25)	1 (5.6)	0.32
IgG N(%)	4 (30.8)	6 (33.3)	1.00
IgM and/or IgG N (%)	4 (30.8)	6 (33.3)	1.00
IgM and IgG N(%)	2 (16.7)	1 (5.6)	
a*β*2GP1 only N(%)	0 (0)	2 (11.1)	0.214
Nº aPL			
1 N (%)	6 (46.2)	8 (44.4)	1.00
2 N (%)	0 (0)	3 (16.7)	0.35
3 N (%)	4 (30.8)	4 (22.2)	0.90
Thrombotic aPL profile			
Low N (%)	3 (23.1)	5 (27.8)	1.00
High N (%)	10 (76.9)	13 (72.2)	1.00

Abbreviations: antiphospholipid autoantibodies (aPL); anti β2 glycoprotein B1 (aβ2GP1); anti cardiolipin (aCL); Lupus anticoagulant (LA).

Supplementary table 2. Correlation analysis between coagulant activity of FXI and anticardiolipin and antiβ2GP1 antibody titre.

	FXI:C (SS)		**FXI:C (SFX)**	
	Correlation coeficient	**p**	Correlation coeficient	**p**
aβ2GP1 IgM	-0.23	**0.002**	-0.21	**0.005**
aβ2GP1 IgG	-0.22	**0.002**	-0.16	**0.031**
aCL IgM	-0.15	**0.034**	-0.14	0.057
aCL IgG	-0.197	**0.006**	-0.13	0.081

Abbreviations: anti β2 glycoprotein B1 (aβ2GP1); anti cardiolipin (aCL).

Supplementary table 3. Genetic defects, FXI:C and type of FXI deficiency detected in 4 cases with congenital FXI deficiency identified in this study.

Patient	Group	cDNA variant	Protein variant	FXI:C	Type of deficiency	Reference HGMD
P1	APS	c.403G>T	p.Glu135Ter	50%	CRM-	CM890042
P2	AaPL	c.403G>T	p.Glu135Ter	49%	CRM-	CM890042
P3	AaPL	c.802C>T	p.Arg268Cys	44%	CRM-	CM035499
P4	HC	c.1327C>T	p.Arg443Cys	23%	CRM-	CM062624

Abbreviations: Asymptomatic carriers of antiphospholipid antibodies (AaPL); Healthy controls (HC); Primary antiphospholipid syndrome (APS).